MX2019006939A - Preparacion liquida parenteral que comprende compuesto de carbamato. - Google Patents
Preparacion liquida parenteral que comprende compuesto de carbamato.Info
- Publication number
- MX2019006939A MX2019006939A MX2019006939A MX2019006939A MX2019006939A MX 2019006939 A MX2019006939 A MX 2019006939A MX 2019006939 A MX2019006939 A MX 2019006939A MX 2019006939 A MX2019006939 A MX 2019006939A MX 2019006939 A MX2019006939 A MX 2019006939A
- Authority
- MX
- Mexico
- Prior art keywords
- liquid preparation
- carbamate compound
- parenteral liquid
- preparation including
- including carbamate
- Prior art date
Links
- -1 CARBAMATE COMPOUND Chemical class 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La presente invención se relaciona a una preparación líquida parenteral que contiene, como ingredientes activos; un compuesto de carbamato de la fórmula química 1, un isómero del mismo, o una sal, un solvato o un hidrato farmacéuticamente aceptable del mismo; y un derivado de ciclodextrina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 | ||
| PCT/KR2017/014727 WO2018111000A1 (ko) | 2016-12-14 | 2017-12-14 | 카바메이트 화합물을 포함하는 비경구용 액상 제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006939A true MX2019006939A (es) | 2019-09-13 |
| MX390841B MX390841B (es) | 2025-03-21 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006939A MX390841B (es) | 2016-12-14 | 2017-12-14 | Preparacion liquida parenteral que comprende compuesto de carbamato. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (es) |
| EP (1) | EP3556349B1 (es) |
| JP (1) | JP7110196B2 (es) |
| KR (1) | KR102605030B1 (es) |
| CN (2) | CN118766839A (es) |
| AU (1) | AU2017374450B2 (es) |
| CA (1) | CA3046458A1 (es) |
| CL (1) | CL2019001617A1 (es) |
| DK (1) | DK3556349T3 (es) |
| ES (1) | ES2901427T3 (es) |
| IL (1) | IL267192B2 (es) |
| MX (1) | MX390841B (es) |
| MY (1) | MY200159A (es) |
| PL (1) | PL3556349T3 (es) |
| PT (1) | PT3556349T (es) |
| RU (1) | RU2761041C2 (es) |
| WO (1) | WO2018111000A1 (es) |
| ZA (1) | ZA201903748B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3711758T3 (pl) | 2017-11-14 | 2024-07-01 | Sk Biopharmaceuticals Co., Ltd. | Zastosowanie związku karbaminianowego do zapobiegania, łagodzenia lub leczenia napadów nieświadomości lub padaczki wykazującej napady nieświadomości |
| WO2020060251A1 (ko) * | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도 |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| WO2007041524A2 (en) * | 2005-09-30 | 2007-04-12 | Ovation Pharmaceuticals, Inc. | Novel parenteral carbamazepine formulation |
| CN101578103B (zh) * | 2006-06-29 | 2013-09-25 | 林科杰诺米克斯株式会社 | 抗生素的注射剂及其给予液 |
| CN101686681B (zh) * | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| JP5683580B2 (ja) | 2009-06-22 | 2015-03-11 | エスケー バイオファーマシューティカル カンパニー リミテッド | カルバミン酸（ｒ）−１−アリール−２−テトラゾリル−エチルエステルの製造方法 |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
- 2017-12-14 CA CA3046458A patent/CA3046458A1/en active Pending
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/en unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267192B2 (en) | 2023-05-01 |
| CN110267647A (zh) | 2019-09-20 |
| CL2019001617A1 (es) | 2019-08-23 |
| MY200159A (en) | 2023-12-09 |
| RU2761041C2 (ru) | 2021-12-02 |
| DK3556349T3 (da) | 2022-01-03 |
| BR112019011914A2 (pt) | 2019-11-05 |
| US20190314336A1 (en) | 2019-10-17 |
| AU2017374450B2 (en) | 2023-05-11 |
| JP2020502108A (ja) | 2020-01-23 |
| PL3556349T3 (pl) | 2022-04-11 |
| IL267192A (es) | 2019-07-31 |
| EP3556349B1 (en) | 2021-11-24 |
| EP3556349A4 (en) | 2020-07-01 |
| MX390841B (es) | 2025-03-21 |
| ZA201903748B (en) | 2020-12-23 |
| KR20190087568A (ko) | 2019-07-24 |
| WO2018111000A1 (ko) | 2018-06-21 |
| IL267192B1 (en) | 2023-01-01 |
| EP3556349A1 (en) | 2019-10-23 |
| RU2019121911A (ru) | 2021-01-15 |
| KR102605030B1 (ko) | 2023-11-23 |
| CN118766839A (zh) | 2024-10-15 |
| JP7110196B2 (ja) | 2022-08-01 |
| US12070447B2 (en) | 2024-08-27 |
| US20240374568A1 (en) | 2024-11-14 |
| ES2901427T3 (es) | 2022-03-22 |
| CA3046458A1 (en) | 2018-06-21 |
| AU2017374450A1 (en) | 2019-07-04 |
| RU2019121911A3 (es) | 2021-03-05 |
| PT3556349T (pt) | 2021-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| MX391538B (es) | Proceso de compuesto antifungico. | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MY192425A (en) | Polymorphs | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| MY194116A (en) | Pharmaceutical compounds | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. | |
| TN2016000489A1 (en) | Carboxamide derivatives. | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| MX2019006939A (es) | Preparacion liquida parenteral que comprende compuesto de carbamato. |